Category: M&A

MEwens
Deconstructing the deal’s CVR; solving Genzyme’s manufacturing problems; avoiding the pitfalls of pharma-biotech deals; Viehbacher’s legacy.
Read more this great post here

MEwens
For the French pharma company, the deal’s immediate benefits may be more important.
Read more this great post here

MEwens
Also: results for a faster flu-vaccine production method; generic-drug makers want to pay user fees; malpractice law changes.
Read more this great post here

MEwens
In only one recent case — OSI Pharmaceuticals’ 2003 purchase of Cell Pathways — is the result clear.
Read more this great post here

MEwens
Also: President Obama’s 2012 budget due out today; new 3-D mammography system approved; retirees’ health benefits.
Read more this great post here

Katherine Hobson
Also: One syphilis test has high false-positive rate; MannKind cuts workforce; ideal pain relief for labor?
Read more this great post here

Katherine Hobson
Also: GSK reportedly settles Avandia claims; Avastin results for ovarian cancer; no defunding of health law in spending bill?
Read more this great post here

MEwens
Also: alternatives to the individual mandate; formula-fed infants, solid food and obesity; pharmacy robberies.
Read more this great post here

MEwens
Also: the seriously ill worry about fate of the health law; Avastin side effects; lobbying to restore FSA eligibility.
Read more this great post here

MEwens
Also: Roche gives back rights to a diabetes drug; drug shortages; a new kind of primary-care practice.
Read more this great post here